ORMP Oramed Pharmaceuticals
- 2.380
- -0.050-2.06%
Oramed Pharmaceuticals News
Oramed Pharmaceuticals (ORMP.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $666,000; earnings per share of $0.04, previous value of -$0.08, and expected value of $0.02.
Oramed Pharmaceuticals (ORMP.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $666,000; earnings per share of $0.04, previous value of -$0.08, and expected value of $0.02.
Oramed Pharmaceuticals | 10-Q: Quarterly report
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Plans New US Trial for Oral Insulin After Setback, Partners With HTIT to Commercialize Products
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
MQ, ORMP and EXAI Are Among Pre Market Gainers
Top 4 Health Care Stocks That May Crash This Quarter
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related A
Oramed Pharmaceuticals Said On Jan 22, Co And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl; Oramed And HTIT Will Initially Hold Equal Shares In JV, With Each Owning 50% Of Equity
Oramed Pharmaceuticals Said On Jan 22, Co And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl; Oramed And HTIT Will Initially Hold Equal Shares In JV, With Each Ownin
PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization
PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 ...
OKTA, AMWL and ORMP Among Pre-market Losers
Oramed Pharmaceuticals (NASDAQ:ORMP) Investors Are Sitting on a Loss of 63% If They Invested a Year Ago
Oramed Pharmaceuticals Secures $101.9M Senior Secured Note Deal With Scilex
An initial principal balance of $101,875,000.00;A senior lien for Oramed on substantially all assets of Scilex and its subsidiaries, subject to certain exclusions;18-month maturity;Certain mandatory p
Press Release: Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction With Scilex Holding Company
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company PR Newswire NEW YORK, Sept. 21, 2023 -- 18-month loan with interest rate of SOFR plus 8.5%
Scilex Assumed $100M In Debt Owed To Oramed Pharmaceuticals And Issued A Promissory Note And Warrants To Oramed As Part Of The Securities Transfer.
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex Holding Company Announces The Consummation Of The Previously Announced Purchase Of All Of The Scilex Common Shares, Preferred Shares And Warrants Owned By Sorrento Therapeutics, Inc.
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex to Acquire Sorrento-owned Stake
Analysis
Price Target
No Data
